Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

Bariatric surgeries: These are operations that remove or bypass part of the stomach for the purpose of losing weight and ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

TUCSON, AZ / ACCESS Newswire / June 2, 2025 / Umbrella Labs , a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an ...

THURSDAY, May 15, 2025 (HealthDay News) -- Glucagon-like peptide-1 receptor ... treated with a first-generation GLP-1 RA or with bariatric metabolic surgery (BMS). Analysis included 3,178 matched ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

Findings for matched groups of patients with obesity and diabetes taking first-generation GLP-1 RA or undergoing bariatric metabolic surgery. (HealthDay News) — Glucagon-like peptide-1 receptor ...